Recordati S.p.A. - Recordati licences silodosin from Kissei for the whole of Europe

Press Releases

Recordati licences silodosin from Kissei for the whole of Europe

Milan, 13 December, 2004

Recordati announced that it has entered into a license agreement with Kissei Pharmaceutical Co., Ltd., a Japanese pharmaceutical company, for the development and marketing of silodosin, a new compound discovered by Kissei for the treatment of symptoms associated with benign prostatic hyperplasia, in all European countries.

Silodosin is a selective alpha-1A receptor antagonist which relaxes smooth muscles at the prostate and the urethra. Urinary resistance is consequently decreased and thus symptoms associated with benign prostatic hyperplasia are alleviated. This condition is frequently observed in ageing men and its symptoms significantly reduce quality of life. Benign prostatic hyperplasia is increasing in frequency due to the progressive ageing of the population.

The drug has already completed its development in Japan where a new drug application has been filed. Under this agreement Recordati obtains exclusive rights to silodosin for Europe (45 countries) where it will complete its clinical development and following approval will market and sell it.

"This agreement further confirms our strategy to enrich our product pipeline through partnerships and to expand our pharmaceutical operations into other European countries" declared Giovanni Recordati, Chairman and CEO. "The silodosin agreement reflects our commitment to the research and development of treatments for urological disorders and complements our own original programs involving candidates for the treatment of other micturition disorders. We are looking forward to our collaboration with Kissei and through Kissei with Watson Pharmaceuticals, who will be developing the product for the North American market, to take advantage of opportunities for co-operation and synergies between the European and U.S. development programs."

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003074447), dedicated to the research, development, manufacturing and marketing of pharmaceuticals and pharmaceutical chemicals, with headquarters in Milan, Italy and operating subsidiaries in France, Ireland, Spain, Switzerland and the United States.

		Home Site Map Alert Service Versione Italiana
About us Pharmaceutical operations Rare diseases Investors Corporate Governance Publications Join Us Contacts
Home Investors Press Releases 2004 Print Page Bookmark Page
Recordati at a glance Key Financial Data Recordati Share Press Releases 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 Company Presentations Annual and Interim Reports Regulated information Shareholders’ Meetings Calendar Analyst Coverage Contacts	Press Releases Recordati licences silodosin from Kissei for the whole of Europe Milan, 13 December, 2004 Recordati announced that it has entered into a license agreement with Kissei Pharmaceutical Co., Ltd., a Japanese pharmaceutical company, for the development and marketing of silodosin, a new compound discovered by Kissei for the treatment of symptoms associated with benign prostatic hyperplasia, in all European countries. Silodosin is a selective alpha-1A receptor antagonist which relaxes smooth muscles at the prostate and the urethra. Urinary resistance is consequently decreased and thus symptoms associated with benign prostatic hyperplasia are alleviated. This condition is frequently observed in ageing men and its symptoms significantly reduce quality of life. Benign prostatic hyperplasia is increasing in frequency due to the progressive ageing of the population. The drug has already completed its development in Japan where a new drug application has been filed. Under this agreement Recordati obtains exclusive rights to silodosin for Europe (45 countries) where it will complete its clinical development and following approval will market and sell it. "This agreement further confirms our strategy to enrich our product pipeline through partnerships and to expand our pharmaceutical operations into other European countries" declared Giovanni Recordati, Chairman and CEO. "The silodosin agreement reflects our commitment to the research and development of treatments for urological disorders and complements our own original programs involving candidates for the treatment of other micturition disorders. We are looking forward to our collaboration with Kissei and through Kissei with Watson Pharmaceuticals, who will be developing the product for the North American market, to take advantage of opportunities for co-operation and synergies between the European and U.S. development programs." Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003074447), dedicated to the research, development, manufacturing and marketing of pharmaceuticals and pharmaceutical chemicals, with headquarters in Milan, Italy and operating subsidiaries in France, Ireland, Spain, Switzerland and the United States.